Skip to main
IVA
IVA logo

Inventiva S.A. (IVA) Stock Forecast & Price Target

Inventiva S.A. (IVA) Analyst Ratings

Based on 6 analyst ratings
Buy
Strong Buy 67%
Buy 17%
Hold 17%
Sell 0%
Strong Sell 0%

Bulls say

Inventiva SA is focused on developing lanifibranor, a promising candidate for treating non-alcoholic steatohepatitis (NASH), with the potential to benefit a specific patient group: T2D positive MASH patients, who are seen as a particularly viable market. The Phase II NATIVE study has demonstrated lanifibranor's anti-fibrotic effects, reinforcing the drug's potential value in a high-demand area lacking approved therapies. Furthermore, the company's significant revenue from research partnerships with major pharmaceutical companies like AbbVie and BI underscores its strong position within the biopharmaceutical landscape.

Bears say

Inventiva SA is a biopharmaceutical company focused on developing therapies for conditions such as NASH, with its primary product candidate, lanifibranor, currently in Phase III clinical trials. There are concerns regarding high turnover in key regulatory roles, particularly the CEO and CMO, which may adversely affect the company's stability and share performance. Additionally, any efficacy or safety issues arising from lanifibranor during its clinical development could significantly undermine investor confidence and exacerbate the negative outlook on the stock.

Inventiva S.A. (IVA) has been analyzed by 6 analysts, with a consensus rating of Buy. 67% of analysts recommend a Strong Buy, 17% recommend Buy, 17% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Inventiva S.A. and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Inventiva S.A. (IVA) Forecast

Analysts have given Inventiva S.A. (IVA) a Buy based on their latest research and market trends.

According to 6 analysts, Inventiva S.A. (IVA) has a Buy consensus rating as of Oct 14, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $17.17, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $17.17, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Inventiva S.A. (IVA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.